Evaluation of Cangrelor Use After Percutaneous Coronary Intervention in Patients With Mechanical Circulatory Support
Authors' conclusion
For patients receiving cangrelor as a bridge to oral P2Y12 inhibitor therapy on mechanical circulatory support, the authors observed a low rate of major bleeding and no episodes of thrombosis.
Study context
- Population
- Adults ≥18 years in the ICU after PCI with stent placement, on mechanical circulatory support, receiving cangrelor post-PCI
- Participants
- 19 adults
- Outcome
- Incidence of thrombosis and bleeding events during cangrelor administration
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
Thrombosis and bleeding events during cangrelor administration
Any bleeding event
14 patients
74%
Bleeds classified as minor
93%
Major bleeding events
1
Thrombotic events
0
Observational data: associations, not effects.
Further findings
| Outcome | Values |
|---|---|
| Initial cangrelor dose | Cangrelor median 0.5 µg/kg/min |
| Survival from mechanical circulatory support | Cangrelor 89% |
| Mortality · 30 days | Cangrelor 42% |
Dose adjustments
- Patients with dose adjustment, mostly reductions based on antiplatelet monitoring (VerifyNow assay)
- 10
Safety
Bleeding and thrombosis during cangrelor administration
- Patients with a bleeding event
- 14 (74%)
- Bleeds classified as minor
- 93%
- Major bleeding events
- 1
- Thrombotic events during cangrelor administration
- 0
Original publication
Evaluation of Cangrelor Use After Percutaneous Coronary Intervention in Patients With Mechanical Circulatory Support. J Cardiothorac Vasc Anesth. Published 6 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →